Abstract:Guru Subramanian Guru Murthy Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA Correspondence: Guru Subramanian Guru Murthy, Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA, Tel +1 414-805-4600, Fax +1 414-805-6815, Email The management of chronic myeloid leukemia (CML) has remarkably changed in the last 20 years with the availability of tyrosine kinase inhibitors (TKI). Most patients with chronic phase CML now have a life expectancy like that of age matched controls. Understanding the practical aspects of choosing the appropriate TKI, monitoring response and side-effects are key to long term success. Currently, treatment cessation is also an option in patients achieving sustained deep molecular response. Novel agents are needed in patients with lack of response to TKI and in those with advanced disease. Keywords: leukemia, myeloid, chronic, treatment Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of t (9, 22) leading to BCR-ABL1 gene rearrangement. In United States, it is diagnosed at a median age of 67 years with about 8450 new cases in 2020. 1 Although CML was considered as a deadly disease in the past, the availability of BCR-ABL tyrosine kinase inhibitors (TKI) have remarkably changed the outlook of this disease. Currently, CML is considered as a disease that is well manageable with oral TKI giving excellent long-term results and the option for stopping treatment in some patients. In this review, we will discuss about the practical aspects of managing CML and the common considerations given at various levels of management. Most patients with CML present with leukocytosis and left shifted granulocytes, and/or thrombocytosis. Symptoms at presentation are variable and could include fever, night sweats, fatigue, and some patients are asymptomatic. To diagnose CML, the demonstration of the Philadelphia chromosome abnormality or the BCR-ABL gene rearrangement is important. At the cytogenetic level, CML is characterized by a reciprocal translocation in chromosomes 9 and 22. 2 This leads to the fusion of BCR and ABL1 genes. The breakpoint typically occurs in introns 13 or 14 of the BCR gene in chromosome 22 and exons 1 or 2 of ABL1 in chromosome 9. This results in the typical transcripts (e13a2 or e14a2) and major fusion protein (p210). In some patients, the break points can occur at other exon location (e1a2 with p190, e19a2 with p230, e13a3, e14a3) and should be considered if the classical major BCR is not present. Confirmation of t (9, 22) can be done using conventional karyotyping or Fluorescence-in-situ-hybridization studies and the identification and quantitation of the BCR-ABL1 fusion transcripts can be done using polymerase chain reaction (PCR). Testing can be done either from the peripheral blood or bone marrow specimens, although, obtaining a bone marrow biopsy at baseline would also assist in confirming the disease phase and provide an opportunity to assess for additional chromosomal abnormalities. Once a diagnosis established, it is important to know the disease phase and the risk status to determine the optimal first line therapy. CML has 3 phases - chronic, accelerated and blast phase. While most of the patients diagnosed with CML are in chronic phase, some patients have higher disease risk with presentations such as accelerated or blast phase. Knowing the disease phase is important as the management and prognosis differs significantly based on this aspect. Patients with chronic phase CML now have a survival that is similar to age matched controls without CML, but patients with blast phase CML have a median survival of 7–11 months. 3,4 Chronic phase CML can be risk stratified using Sokal risk score (used more commonly in US) based on age, spleen size by clinical exam, platelet counts and peripheral blast percentage. 5 This stratification helps in understanding the prognosis and choosing the first line therapy. Currently, imatinib, dasatinib, nilotinib and bosutinib are available as first line options for management of CML. Imatinib is a first generation TKI that was compared against interferon and cytarabine for newly diagnosed CML and showed significantly higher response rates (major cytogenetic response 87.1% vs 34.1%) and lower risk of transformation to accelerated or blast phase (freedom from progression 96.7% vs 91.5%). 6 Subsequently, second generation TKI such as dasatinib, nilotinib, and bosutinib were compared against imatinib in prospective clinical studies and showed encouraging efficacy 7–12 (Table 1). In general, starting treatment with second generation TKI would lead to quicker achievement of cytogenetic and molecular responses, minimizes the risk of transformation to accelerated phase or bl -Abstract Truncated-

Chronic myelogenous leukemia: elements of conventional chemotherapy and an overview of autografting in the treatment of the chronic phase

[Clinical Observation of Gleevec Combined with Myeloablative Allogeneic Stem Cells Transplantation in Treatment of Chronic Myeloid Leukemia].

[Cytogenetic and Molecular Analysis of 1193 Cases with Chronic Myeloid Leukemia].

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products

Leukemia Stem Cells: the Root of Chronic Myeloid Leukemia

Cytogenetics and genomics in CML and other myeloproliferative neoplasms

Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia

The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia

Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management

Control of Ph+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors

An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia

Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia

Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia